首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷

市場調查報告書

商品編碼

1593445

臨床試驗影像市場規模、佔有率、成長分析、按服務/軟體、按模式、按治療領域、按最終用戶、按地區 - 產業預測，2024-2031年

Clinical Trial Imaging Market Size, Share, Growth Analysis, By Service and Software, By Modality, By Therapeutic Area, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月14日 | 出版商:

SkyQuest | 英文 194 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年臨床試驗影像的全球市場規模為12.2億美元，預計從2023年的13.2億美元成長到2031年的24.2億美元，在預測期間（2024-2031年）將以7.82％的年複合成長率成長。

生物技術和製藥行業預計將強勁成長，這主要是由於目的是為各種疾病創造新藥的研發投資激增。這種成長與醫療影像領域的顯著併購趨勢相輔相成，目的是增強醫療設備製造並整合先進成像技術以改善臨床測試。儘管醫療影像產業具有動態性，但在醫療影像公司大量資本配置的推動下，該產業呈現出穩定的動力。技術進步徹底改變了臨床試驗影像資料的收集、分析和呈現。特別是，影像分析軟體已成為臨床研究中的重要工具，透過增強的資料管理方法提供一致性、準確性、擴充性和法規遵循等優勢。此外，對電腦技術的更多依賴和增強的計算能力預計將進一步提高臨床試驗中的影像處理能力。定量成像生物標記聯盟（QIBA）通訊協定的建立引進了標準化的資料收集方法，確保臨床試驗中採用的方法產生真實且可比較的資料。因此，成像技術不斷發展，使生物技術和製藥產業能夠在面對持續的醫療挑戰時實現持續成長和創新。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東、非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

ICON plc
Medpace
Clario
IXICO plc
Resonance Health Ltd.
Radiant Sage
WCG Clinical
Medical Metrics, Inc.
Prism Clinical Imaging
Boston Imaging Core Lab
Voiant
Calyx
Biospective Inc.
Micron, Inc.
Imaging Endpoints
Perspectum
Competence Network Life Sciences（Pharmtrace）
Median Technologies
Image Core Lab
Image Analysis Group（IAG）

簡介目錄

Product Code: SQMIG35H2309

Global Clinical Trial Imaging Market size was valued at USD 1.22 billion in 2022 and is poised to grow from USD 1.32 billion in 2023 to USD 2.42 billion by 2031, growing at a CAGR of 7.82% during the forecast period (2024-2031).

The biotechnology and pharmaceutical sectors are poised for robust growth, primarily driven by escalating investments in research and development aimed at creating new drugs for a variety of diseases. This growth is complemented by a noteworthy trend of mergers and acquisitions within the medical imaging domain, which seek to integrate advanced imaging technologies to enhance the manufacturing of medical devices and improve clinical investigations. Despite the dynamic nature of the medical imaging landscape, these industries are seeing steady momentum, propelled by significant capital allocation toward medical imaging firms. Technological advancements have revolutionized the collection, analysis, and presentation of clinical trial imaging data. Notably, image analysis software has emerged as a pivotal tool in clinical research, offering benefits such as increased consistency, accuracy, scalability, and regulatory compliance through enhanced data management methods. Additionally, the growing reliance on computer technology and augmented computing power is expected to further enrich imaging capabilities in clinical trials. The establishment of the Quantitative Imaging Biomarker Alliance (QIBA) protocol has introduced standardized techniques for data collection, ensuring that methodologies employed in clinical trials yield realistic and comparable data. As a result, imaging techniques continue to evolve, positioning the biotechnology and pharmaceutical industries for sustained growth and innovation in the face of ongoing medical challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Clinical Trial Imaging market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Clinical Trial Imaging Market Segmental Analysis

Global Clinical Trial Imaging Market is segmented by Service and Software, Modality, Therapeutic Area, End User, and Region. Based on Service and Software, the market is segmented into Services (Operational Imaging Services, Read Analysis Services, System And Technical Support Services, Trial Design And Consulting Services), Software. Based on Modality, the market is segmented into Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-Ray, Others. Based on Therapeutic Area, the market is segmented into Oncology, Infectious Diseases, Neurology, Cardiovascular System Disorders, Endocrinology, Immunological Disorders, Others. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic And Government Research Institutes, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Clinical Trial Imaging Market

The Global Clinical Trial Imaging market is significantly propelled by rising investments in research and development (R&D) activities within the pharmaceutical and biotechnology sectors. As the complexity of drug development escalates, the demand for precise imaging technologies becomes paramount to effectively monitor treatment outcomes and disease progression during clinical trials. Advanced imaging modalities such as MRI, PET, and CT scans provide essential data that enhances the understanding of a therapy's safety and efficacy, which is critical for regulatory approvals. This growing reliance on sophisticated imaging techniques not only supports the validation of new treatments but also drives innovation and competitiveness in the market.

Restraints in the Global Clinical Trial Imaging Market

The Global Clinical Trial Imaging market faces a significant restraint due to the high costs associated with advanced imaging technologies, such as MRI, PET, and CT scans. These elevated prices can substantially inflate the overall expenses of clinical trials, posing a particular challenge for smaller pharmaceutical companies and research institutions that may lack the financial resources to incorporate these sophisticated imaging modalities. Furthermore, the need for specialized technicians and radiologists further exacerbates the financial burden, often leading to a preference for more conventional imaging methods. This financial strain limits the capacity of many organizations to leverage advanced imaging, potentially stunting innovation and slowing down the progress of clinical research.

Market Trends of the Global Clinical Trial Imaging Market

The Global Clinical Trial Imaging market is experiencing a significant trend towards integrating Artificial Intelligence (AI) and machine learning technologies into imaging systems. This innovation enhances the precision and efficiency of image analysis, significantly minimizing human error and accelerating result turnaround times. AI-driven tools are automating complex imaging processes, which not only streamlines the clinical diagnostic workflow but also makes advanced imaging techniques more accessible and cost-effective. As healthcare stakeholders increasingly recognize the benefits of AI in improving clinical trial outcomes, the demand for these cutting-edge imaging solutions is poised for continued growth, shaping the future of clinical research.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Ecosystem of the Market
Patent Analysis
Pricing Analysis
Trade Analysis
Value Chain Analysis
Supply Chain Analysis
Customer & Buying Criteria Analysis
Case Study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Clinical Trial Imaging Market by Service and Software

Market Overview
Services
- Operational Imaging Services
- Read Analysis Services
- System & Technical Support Services
- Trial Design & Consulting Services
Software

Clinical Trial Imaging Market by Modality

Market Overview
Computed Tomography
Magnetic Resonance Imaging
Ultrasound
Positron Emission Tomography
X-Ray
Others

Clinical Trial Imaging Market by Therapeutic Area

Market Overview
Oncology
Infectious Diseases
Neurology
Cardiovascular System Disorders
Endocrinology
Immunological Disorders
Others

Clinical Trial Imaging Market by End User

Market Overview
Pharmaceutical & Biotechnology Companies
Medical Device Manufacturers
Contract Research Organizations
Academic And Government Research Institutes
Others

Clinical Trial Imaging Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

ICON plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medpace
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clario
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IXICO plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Resonance Health Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radiant Sage
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WCG Clinical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medical Metrics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Prism Clinical Imaging
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Imaging Core Lab
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Voiant
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Calyx
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biospective Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Micron, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imaging Endpoints
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Perspectum
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Competence Network Life Sciences (Pharmtrace)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Median Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Image Core Lab
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Image Analysis Group (IAG)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments